Antidote
FEBRUARY 27, 2023
Participating in a clinical trial has many benefits, including working with condition specialists, getting access to personalized medical care, and helping science move forward — but did you know that some clinical trials offer compensation, as well?
Drug Patent Watch
FEBRUARY 25, 2023
This chart shows the pharmaceutical companies with the most patents in Serbia. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is… The post Which pharmaceutical companies have the most drug patents in Serbia? appeared first on DrugPatentWatch - Make Better Decisions.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
NIOSH Science Blog: Drugs
FEBRUARY 27, 2023
Coal mine dust causes a range of lung diseases, collectively called coal mine dust lung diseases. Examples include coal workers’ pneumoconiosis (CWP, a dust-induced scarring lung disease commonly called black lung), chronic obstructive pulmonary disease (COPD), and lung function impairment. All of these cause substantial morbidity (illness) and mortality (death) among affected coal miners.[1–5] Most attention in the U.S. has focused on CWP, especially its most severe stage called progressive mas
Drug Channels
MARCH 3, 2023
Today’s guest post comes from Jan Nielsen, Patient Solutions Division President at AssistRx. Jan discusses digital hubs and the benefits they offer both patients on specialty therapies and their health care providers. To learn more, download AssistRx's free 61-page eBook: Specialty Drug Patient Support Programs: 2022 Progress Report. Read on for Jan’s insights.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Cytel
MARCH 3, 2023
The speed of scientific discovery has been outpacing the ability of researchers to accumulate and integrate constantly evolving new insights into systematic literature reviews (SLRs). This gets compounded by obstacles to accessing the newest publications. For one pharmaceutical company looking to evaluate the potential impact of surrogate endpoints on long-term clinical outcomes in multiple myeloma, an SLR was needed in just two months for the research to support reimbursement submissions.
Drug Patent Watch
FEBRUARY 27, 2023
Annual Drug Patent Expirations for XHANCE Xhance is a drug marketed by Optinose Us Inc and is included in one NDA. It is available from one supplier. There are thirteen… The post New patent for Optinose Us drug XHANCE appeared first on DrugPatentWatch - Make Better Decisions.
Drug Discovery Digest brings together the best content for drug research and development professionals from the widest variety of industry thought leaders.
Drug Channels
FEBRUARY 28, 2023
The era of artificial-intelligence chatbots has arrived! I am pleased to report that this month’s Drug Channels news roundup was most definitely not written by ChatGPT. No promises about future articles. (See our forecast to the right.) In this issue: Mark Cuban explains his anti-PBM strategy What physicians think about Humira biosimilars States go after PBMs HHS is confused about 340B transparency Plus, The Onion tests your knowledge of United Healthcare’s policies.
Crown Bioscience
MARCH 3, 2023
The use of more clinically relevant preclinical models can help to reduce anticancer drug attrition rates by providing a better understanding of the safety, efficacy, and mechanism of a drug candidate, which can help inform downstream decisions.
Drug Patent Watch
MARCH 3, 2023
Annual Drug Patent Expirations for NORMOCARB+HF+25 Normocarb Hf 25 is a drug marketed by Dialysis Sups and is included in one NDA. There is one patent protecting this drug. This… The post New patent expiration for Dialysis Sups drug NORMOCARB HF 25 appeared first on DrugPatentWatch - Make Better Decisions.
BenchSci
MARCH 3, 2023
Diversity, equity, and inclusion are important to us at BenchSci and as a part of our DEI journey we are committed to learning about, celebrating, and amplifying the voices and accomplishments of people from diverse backgrounds.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
ACTO
MARCH 3, 2023
Launching a new product in the Life Sciences industry is no easy feat. It requires a significant investment of time, resources, and expertise and can ultimately make or break a company’s success. However, despite the high stakes involved, success is far from guaranteed. The lack of a clear blueprint for success in product launches can leave teams feeling lost and unsure how to proceed.
Olympian Clinical Research
MARCH 3, 2023
While many people think of eczema as an issue that mainly affects children, the skin condition may also manifest later in life. The triggers and causes of eczema in adults may vary from person to person. If you suffer from dry, itchy skin and red rashes on your body, then chances are you have a form of eczema known as atopic dermatitis ( AD ). When AD develops after your 18th birthday, it is known as adult-onset atopic dermatitis.
Drug Patent Watch
MARCH 3, 2023
This chart shows the pharmaceutical companies with the most supplementary protection certificates (SPCs) in Italy. SPCs are used in European Union and select others to encourage pharmaceutical innovation by compensating… The post Which pharmaceutical companies have the most SPCs in Italy? appeared first on DrugPatentWatch - Make Better Decisions.
sptlabtech
MARCH 2, 2023
On January 25th I had the pleasure of attending the Festival of Genomics and Biodata that returned as an in-person event after being held virtually for two years. It truly returned with a bang, bigger and busier than ever, with eight streams of scientific talks, over 90 exhibitors, and over 4000 attendees. It was a vibrant event that attracted a broad range of genomics-minded delegates from academia, industry, and public sector.
Advertisement
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
Metabolite Tales Blog
MARCH 1, 2023
Metabolism of nitrogen containing five-membered aromatic heterocycles nitrogen containing five membered aromatic heterocycle Highlighting trends in oxidation and glucuronidation of these ring systems in drugs By Samuel Coe Five membered nitrogen containing aromatic heterocycles are commonly used in medicinal chemistry for multiple reasons, including reduced lipophilicity compared to phenyl groups, increased metabolic stability and ease of substitution.
The ChEMBL-og
MARCH 1, 2023
We are pleased to announce the release of ChEMBL 32! This release of ChEMBL comes with a complete update of drug and clinical candidate information, the addition on a Natural Product likeness score and a harmonization of Journal Name abbreviations according to NLM standards. This version of the database, prepared on 26/01/2023 contains: 2,354,965 compounds (of which 2,327,928 have mol files) 2,995,433 compound records (non-unique compounds) 20,038,828 activities 1,536,903 assays 15,139 targets 8
Drug Patent Watch
MARCH 3, 2023
Annual Drug Patent Expirations for ZOLINZA Zolinza is a drug marketed by Msd Sub Merck and is included in one NDA. It is available from one supplier. There are nine… The post New patent expiration for Msd Sub drug ZOLINZA appeared first on DrugPatentWatch - Make Better Decisions.
keypoint
MARCH 1, 2023
Today’s Open Access Spotlight goes to Frontiers for Young Minds , a non-profit science journal for kids, BY kids! That’s right, a publication where kids are the reviewers of the latest scientific research. Each article is written by top researchers, including Nobel Prize winners, and is then reviewed by young students aged 8-15. Working with the guidance of Science Mentors locally in 65 countries, Young Reviewers ensure that everything is accessible and engaging for their peers.
Advertisement
Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic
LifeSciVC
MARCH 1, 2023
By Jonathan Montagu, CEO of HotSpot Therapeutics, as part of the From The Trenches feature of LifeSciVC The phrase ‘build it and they will come’ dates all the way back to the Old Testament, and in more recent times has been romanticized in movies like Field of Dreams , but the concept also holds true in many areas of science. Even good ideas are met with healthy skepticism for the practical and technical limitations of being able to effectively test a hypothesis.
Conversations in Drug Development Trends
MARCH 1, 2023
The advent of outsourcing in clinical research came about in the 1980s based on transactional business-to-business interactions, which focused on the completion of specific development tasks. Through the 1990s, sponsors required a more sophisticated offering from CROs who were required to master fundamental study operations and processes, offering scalability to sponsors’ operations departments.
Drug Patent Watch
MARCH 2, 2023
This chart shows the drugs with the most supplementary protection certificates (SPCs). SPCs are used in European Union and select others to encourage pharmaceutical innovation by compensating for the long… The post Which drugs have supplementary protection certificates in the most countries? appeared first on DrugPatentWatch - Make Better Decisions.
Predictive Oncology
FEBRUARY 28, 2023
Proactive Investor’s Natalie Stoberman met with Raymond F. Vennare, CEO of Predictive Oncology, and Javier Torres-Roca, MD, Co-Founder and CEO of Cvergenx, Inc., to discuss a strategic partnership to create the first-ever genomics-based approach to precision radiation therapy and drug discovery using artificial intelligence. Click here to view the interview and learn more about how this powerful collaboration will leverage Predictive Oncology’s drug discovery, artificial intelligence and machin
BMG Labtech
FEBRUARY 28, 2023
The discovery of an enzyme that removes acetyl groups from histone dates to 1969 when Inoue and Fujimoto discovered histone deacetylase (HDAC) activity in calf thymus extract. 1 This finding, which arose from curiosity-driven research, opened new areas of enquiry, led to a better understanding of epigenetics, and launched a host of clinical investigations for new drugs to treat cancer, inflammation, and neurological diseases.
Advarra
FEBRUARY 28, 2023
This February, Advarra’s “Honoring Clinical Trailblazers” video series paid tribute to the outstanding achievements of four pioneering African American physicians who defied the odds to make significant contributions to the field of medicine. These physicians faced enormous challenges due to their race, gender, and societal barriers, but their passion for helping others and their unwavering commitment to advancing medical knowledge led to groundbreaking discoveries and changes,
Drug Patent Watch
MARCH 2, 2023
Annual Drug Patent Expirations for XYREM Xyrem is a drug marketed by Jazz Pharms and is included in one NDA. It is available from two suppliers. There are eight patents… The post New patent for Jazz Pharms drug XYREM appeared first on DrugPatentWatch - Make Better Decisions.
Conversations in Drug Development Trends
FEBRUARY 28, 2023
95% of rare diseases don’t have a treatment approved and won’t anytime soon. Uplifting Athletes (UA) is on a mission to change that. Back in 2010, Rob Long was a 22-year-old football player at Syracuse University on the path towards his dream career of becoming a punter in the NFL. But just a few months before his college graduation and the start of his career, Rob’s dreams fell to pieces.
Antidote
FEBRUARY 28, 2023
Rare Disease Day occurs every year on the last day of February, and is aimed at raising awareness and creating change for the 300 million individuals across the globe living with a rare disease.
Advarra
FEBRUARY 28, 2023
In an effort to accelerate the sharing of biomedical research results, the National Institutes of Health (NIH) issued its finalized Data Management and Sharing (DMS) policy , effective January 25, 2023. The policy is fundamentally intended to promote and expedite the “translation of research results into knowledge, products, and procedures to improve human health.
Drug Patent Watch
MARCH 1, 2023
This chart shows the patent expirations for tablet dosed drugs over the next decade. The term of drug patents varies. The basic term for a patent is 20 years from… The post Tablet dosed drug patent expirations by year appeared first on DrugPatentWatch - Make Better Decisions.
Covalent Modifiers
FEBRUARY 27, 2023
Wenchao Lu, Yao Liu, Yang Gao, Qixiang Geng, Deepak Gurbani, Lianbo Li, Scott B. Ficarro, Cynthia J. Meyer, Dhiraj Sinha, Inchul You, Jason Tse, Zhixiang He, Wenzhi Ji, Jianwei Che, Audrey Y. Kim, Tengteng Yu, Kenneth Wen, Kenneth C. Anderson, Jarrod A. Marto, Kenneth D. Westover, Tinghu Zhang, and Nathanael S. Gray Journal of Medicinal Chemistry 2023 DOI: 10.1021/acs.jmedchem.2c01834 The c-Jun N-terminal kinases (JNKs) are members of the mitogen-activated protein kinase (MAPK) family, which inc
DS in Pharmatics
FEBRUARY 27, 2023
When pharmaceutical companies develop a new drug product for the market, there are many different steps a potential product must go through to determine and control its safety, manufacturability, effectiveness and reliability. These processes, and all activities within, are known as chemistry, manufacturing, and controls (CMC).
Crown Bioscience
FEBRUARY 27, 2023
Significant progress has been made in the treatment of pediatric cancers, with the 5-year survival rate for children with cancer overall in high-income countries currently at ~80%. Despite this progress, there are still major unmet needs in this patient population. The 5-year survival rate for children with cancer in middle- and low-income countries are ~55% and ~40%, respectively, and survival prospects for several pediatric cancers are still very poor.
Drug Patent Watch
MARCH 1, 2023
Annual Drug Patent Expirations for ARMONAIR+RESPICLICK Armonair Respiclick is a drug marketed by Teva Pharm and is included in one NDA. It is available from one supplier. There are thirteen… The post New patent for Teva Pharm drug ARMONAIR RESPICLICK appeared first on DrugPatentWatch - Make Better Decisions.
Expert insights. Personalized for you.
98 
Let's personalize your content